Biotec Pharmacon ASA Solidifies Efforts In Cancer Adjuvant Therapy
Biotec Pharmacon ASA strengthens its proprietary patent coverage for the combination of monoclonal antibodies and yeast beta glucan for treatment of different types of cancerTROMSØ, NORWAY, February 16, 2012 – Biotec Pharmacon ASA (OSE: BIOTEC) has been issued two patents that cover the combination of monoclonal antibodies and yeast beta glucan for treatment of a large variety of cancers by the Japanese and the Indian Patent Offices. Biotec Pharmacon has developed this concept together with Memorial Sloan-Kettering Cancer Center (MSKCC). Biotec Pharmacon and MSKCC are joint owners of